Metoprolol Ratiopharm (Metoprolol Tartrate)

Metoprolol, a selective β1‑adrenergic blocker, is employed in several cardiovascular disease categories.

• Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest‑pain episodes.
• Post‑myocardial infarction: improves survival by limiting ventricular remodeling and arrhythmias.
• Heart failure: enhances left‑ventricular function and reduces hospitalization rates.
• Cardiac arrhythmias: controls heart rate in atrial fibrillation and other supraventricular tachyarrhythmias.

• Metoprolol Tartrate selectively antagonizes β1‑adrenergic receptors primarily located in cardiac tissue. By blocking catecholamine binding, it reduces cyclic AMP formation, leading to decreased intracellular calcium influx. This results in lowered myocardial contractility, heart rate, and conduction velocity, thereby diminishing cardiac output and oxygen consumption and stabilizing blood pressure.

Metoprolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Fatigue or tiredness
• Dizziness, especially when standing
• Cold extremities or reduced peripheral circulation
• Gastrointestinal upset such as nausea or abdominal discomfort
• Mild bradycardia (slow heart rate)

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention
• Hypotension leading to fainting or shock
• Acute bronchospasm in patients with underlying asthma or COPD
• Worsening heart‑failure symptoms
• Allergic reactions such as rash, angioedema, or anaphylaxis

Before initiating Metoprolol therapy, several precautionary measures should be considered.

• Assess cardiac function: evaluate heart rate, blood pressure, and signs of heart failure.
• Review respiratory history: avoid use in patients with severe asthma or COPD without specialist guidance.
• Monitor glucose: beta blockers may mask hypoglycemia symptoms in diabetic patients.
• Consider renal/hepatic impairment: dose adjustments may be required in reduced clearance.
• Avoid abrupt discontinuation: taper gradually to prevent rebound tachycardia or hypertension.
• Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Metoprolol can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Combined use with non‑selective beta blockers or calcium‑channel blockers (verapamil, diltiazem) may cause excessive bradycardia or AV block.
• Concurrent administration of potent CYP2D6 inhibitors (e.g., paroxetine, quinidine) can markedly increase Metoprolol plasma levels.
• Co‑administration with other antihypertensives (e.g., ACE inhibitors, diuretics) may lead to profound hypotension.

Moderate Interactions (Monitor Closely)

• Antidiabetic agents (insulin, sulfonylureas) may have blunted hypoglycemia warning signs.
• NSAIDs and certain antidepressants can modestly raise blood pressure, counteracting Metoprolol effects.
• Thyroid hormones may reduce the drug’s heart‑rate‑lowering action, requiring dose reassessment.